R&D at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s R&D?
- Recursion Pharmaceuticals, Inc. (RXRX) reported R&D of $87.9M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s R&D changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s R&D decreased by 32.2% year-over-year, from $129.63M to $87.9M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s R&D?
- Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s R&D has grown at a 36.9% compound annual growth rate (CAGR), from $135.27M to $475.27M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.